National Stem Cell is merging with New York-based Azurel, a cosmetic company. National Stem Cell is developing stem cell therapies for diabetes and cardiac injury. Release
Sponsored By Metabolon
Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation
Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.